Concert Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-17,870
Closed -$1.3M 27
2017
Q2
$1.3M Sell
17,870
-12,949
-42% -$871K 1.26% 18
2017
Q1
$1.93M Sell
30,819
-964
-3% -$60.6K 0.44% 52
2016
Q4
$1.99M Sell
31,783
-32,374
-50% -$1.98M 0.44% 51
2016
Q3
$4.04M Sell
64,157
-111
-0.2% -$7.19K 0.49% 35
2016
Q2
$3.97M Buy
64,268
+12,708
+25% +$774K 0.54% 31
2016
Q1
$2.94M Sell
51,560
-1,982
-4% -$110K 0.39% 53
2015
Q4
$3.17M Sell
53,542
-1,745
-3% -$101K 0.42% 47
2015
Q3
$3M Buy
55,287
+7,038
+15% +$458K 0.41% 48
2015
Q2
$3.24M Buy
48,249
+875
+2% +$57.1K 0.42% 43
2015
Q1
$1.22M Buy
47,374
+14,371
+44% +$868K 0.35% 64
2014
Q4
$2.17M Buy
33,003
+5,716
+21% +$360K 0.33% 65
2014
Q3
$1.58M Buy
27,287
+136
+0.5% +$7.55K 0.21% 72
2014
Q2
$1.49M Sell
27,151
-68
-0.2% -$3.57K 0.18% 74
2014
Q1
$1.39M Buy
27,219
+185
+0.7% +$9.35K 0.17% 87
2013
Q4
$1.43M Sell
27,034
-949
-3% -$46.6K 0.18% 84
2013
Q3
$1.25M Sell
27,983
-174
-0.6% -$7.71K 0.18% 90
2013
Q2
$1.15M Buy
+28,157
New +$1.23M 0.17% 85

Other funds holding ABBV

Concert Wealth Management's ABBV Position: Q3 2017 in Review

Concert Wealth Management sold out of AbbVie (ABBV) in Q3 2017, closing a stake of 17,870 shares — an estimated $1.3M sold.

Concert Wealth Management first reported a position in ABBV in Q2 2013 and held it in 17 quarters. The position peaked at $4.04M in Q3 2016. 1,797 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

  • Concert Wealth Management reported no remaining AbbVie position as of Q3 2017 after selling out during the quarter.
  • Concert Wealth Management sold 17,870 AbbVie shares in Q3 2017, an estimated $1.3M.
  • Concert Wealth Management first reported a position in AbbVie in Q2 2013 and held it in 17 quarters.
  • Concert Wealth Management's AbbVie position peaked at $4.04M in Q3 2016.
  • 1,797 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Concert Wealth Management's 13F filing for Q3 2017, filed 14 Nov 2017.